Turkey–France Pharmaceutical Cold-Chain Claims Under CMR: Temperature Excursions, 8.33 SDR and Declared Value

1. CMR governs qualifying Turkey–France pharmaceutical road carriage

Article 1 applies to carriage of goods by road for reward where the place of taking over and place designated for delivery, as specified by the contract, are in different countries and at least one is a Contracting State. Türkiye and France are CMR Contracting States. Pharmaceutical cargo is not excluded from the Convention simply because the shipment is regulated, high-value or temperature-sensitive.

The first legal task is to identify the road-carriage contract. A pharmaceutical manufacturer or distributor may appoint a freight forwarder, a contracting road carrier, a reefer subcontractor, a customs broker and a warehouse. Those entities do not automatically share the same CMR status. The accepted booking, transport order, CMR/e-CMR, invoice for carriage and subcontract records identify who undertook the transport obligation.

The product specification and the carriage instruction also serve different functions. A manufacturer’s storage specification shows the relevant product condition. The carrier’s contractual obligation depends on the instructions communicated and accepted for the carriage. The file should therefore contain both the technical specification and evidence that the agreed transport temperature, mode and handling conditions were actually transmitted to the carrier.

2. A temperature alarm is evidence of an event, not automatic proof of compensable damage

A robust claim identifies the excursion by start time, end time, measured temperature, sensor location and source. Reefer controller data, independent temperature loggers, warehouse records, door-opening events and product probes may record different conditions. Their measurements should not be treated as interchangeable without technical analysis.

Time synchronization is critical on an international route. Record the time zone used by the reefer controller, logger, GPS platform and warehouse system. A one- or two-hour mismatch can falsely place an excursion at a border crossing, unloading event or driver rest stop. Preserve the native files and metadata rather than relying solely on screenshots.

Also preserve evidence of the load configuration. Air circulation can be affected by pallet height, blocked floor channels, product placement, mixed loads and doors. If only one section of a shipment showed an excursion, a pallet map and logger placement can be more probative than an average trailer temperature.

The claimant should avoid a binary “in range/out of range” narrative when the technical data show more complexity. The Convention asks whether damage occurred during the carrier’s period of responsibility and whether a relief rule applies. The technical record must support that causation analysis.

3. Article 18(4) imposes a specific proof condition on refrigerated carriers

Article 17(4)(d) recognizes the special risk associated with the inherent nature of goods that exposes them to particular loss or damage, including decay and similar deterioration. Article 18(2) can give the carrier a presumption when the carrier proves that the loss or damage could be attributed to an Article 17(4) special risk. The claimant can rebut that presumption.

Article 18(4) specifically addresses vehicles specially equipped to protect goods from heat, cold, variations in temperature or humidity. The carrier cannot rely on the Article 17(4)(d) benefit merely by pointing to the inherent sensitivity of the pharmaceuticals. It must prove that it took all steps incumbent on it in the circumstances concerning the choice, maintenance and use of the equipment and that it complied with any special instructions issued to it.

That means the evidence should include the equipment selected for the carriage, maintenance and calibration material, pre-trip inspection where available, set point, operating mode, alarm response, fuel or power continuity where relevant, and actions taken after any fault. If the carrier changed the vehicle, reefer unit or trailer during the journey, the record should cover every relevant segment.

Article 17(3) also prevents the carrier from obtaining relief merely by relying on a defect in the vehicle used for carriage or the fault of the person from whom the vehicle was hired. A leased unit or subcontracted reefer does not by itself shift the CMR claim away from the contracting carrier.

4. The claimant must prove the quality consequence of the excursion

A temperature excursion and product damage are related but separate propositions. Pharmaceuticals can have product-specific stability data, permitted excursion tolerances and quality-release procedures. The CMR claim should therefore include the technical basis on which the affected batch was rejected, downgraded, quarantined or destroyed.

A quality statement should identify the batch, product, storage specification, recorded excursion, duration and the reason the product can no longer be released or marketed. Where a manufacturer or qualified quality function concludes that the batch remains usable, the legal claim must reflect the actual residual value rather than treating the temperature alarm as total destruction.

If a batch is destroyed, preserve the destruction certificate, chain of custody and the decision record. If it is returned, reworked or sold at reduced value, preserve those records and the resulting proceeds. Article 25 measures damage by diminution in value; the residual-value evidence therefore has direct monetary significance.

Where the carrier disputes causation, an independent expert may need the raw temperature data, packaging information, product specification, loading configuration and time history. A conclusion written only after the goods have been destroyed and the data discarded is more difficult to test.

5. Article 23 does not make the invoice amount the automatic compensation figure

Article 23(1) values goods by reference to their value at the place and time at which they were accepted for carriage. Article 23(2) refers first to commodity exchange price, then current market price, and if neither applies, the normal value of goods of the same kind and quality. A commercial invoice is important evidence but does not displace the Convention’s valuation rule.

The 1978 Protocol replaced the historic gold-franc ceiling with 8.33 Special Drawing Rights per kilogram of gross weight short in Article 23(3). For low-weight, high-value pharmaceuticals, this ceiling can be far below the invoice value. A 100-kilogram affected quantity and a multi-million-euro shipment cannot be analysed by assuming that commercial value overrides the treaty ceiling.

Article 23(4) also permits carriage charges, customs duties and other charges incurred in respect of the carriage to be refunded in full for total loss and proportionately for partial loss. Other damages are excluded under the ordinary loss rule. Each claimed expense should therefore be classified under the correct Convention provision rather than added to one general loss figure.

Article 29 can deprive the carrier of Convention exclusions and limits where the damage was caused by wilful misconduct or default considered equivalent under the law of the court or tribunal seized. Article 29 is a separate and fact-intensive exception. A temperature excursion alone does not establish its threshold.

6. High-value pharmaceutical shipments should be checked for Article 24 and Article 26 entries

Article 24 permits the sender, against payment of a surcharge agreed with the carrier, to declare in the consignment note a value exceeding the Article 23(3) limit. When the Convention requirements are met, the declared amount substitutes for the ordinary limit. The declaration must therefore be identified in the carriage documentation; a high invoice value or cargo-insurance value is not the same thing.

Article 26 separately allows the sender, against an agreed surcharge, to fix the amount of a special interest in delivery in the event of loss, damage or exceeding the agreed time limit. If the special interest has been declared, compensation for additional damage proved may be claimed up to the amount declared, within the Convention’s terms.

These provisions are especially relevant for pharmaceuticals because weight can be low compared with commercial value and a delivery failure can have consequences beyond simple physical loss. The booking process should therefore be examined for any agreed surcharge, declared amount and corresponding consignment-note entry.

Do not reconstruct a declaration after the loss. The legal effect depends on what was contractually declared for the carriage. Insurance declarations, customs values and internal risk limits may have other functions and should not be labelled Article 24 or Article 26 declarations unless the Convention requirements are actually met.

7. Article 25 uses diminution in value for damaged pharmaceuticals

When the cargo is damaged rather than lost, Article 25 requires compensation for the amount by which the goods have diminished in value, calculated by reference to the value fixed under Article 23(1), (2) and (4). The legal calculation therefore starts with sound value and residual value.

If the entire consignment has been damaged, Article 25(2)(a) caps compensation at the amount payable if the whole consignment had been lost. If only part has been damaged, Article 25(2)(b) caps compensation at the amount payable if that affected part had been lost. For a shipment containing multiple batches, the file should identify exactly which batch weights and values were affected.

This distinction matters where one logger records an excursion but only adjacent pallets are rejected. Using the gross weight of the entire trailer to increase the CMR ceiling would be incorrect if the established damage concerns a smaller identifiable part. Conversely, where evidence shows that the whole load became commercially unreleasable because the required controlled environment failed, the whole-consignment analysis may be relevant.

Residual value must be real. A theoretical suggestion that rejected pharmaceuticals “could be sold somewhere” is not sufficient without a lawful and commercially available market. Equally, the claimant should account for actual salvage, return credit or reuse obtained.

8. Delivery reservations and Article 32 limitation must be handled separately

Article 30 requires reservations for apparent loss or damage at delivery and written reservations for non-apparent damage within seven days, Sundays and public holidays excepted, stating the general nature of the loss or damage. Temperature-controlled pharmaceutical damage may not be visually apparent on delivery; the written reservation should therefore identify the excursion or quality concern when discovered.

Where carrier and consignee conduct a joint examination, Article 30(2) governs the evidential effect of that examination. A joint inspection should record logger serial numbers, sample locations, product temperatures, visible condition, seal status and any disagreement. A bare signature on a generic delivery note is a weak substitute for a structured record.

Article 32 sets the action limitation period. The ordinary period is one year, extended to three years in the wilful-misconduct/equivalent-default case described by the Convention. For damage, time runs from the date of delivery. A written claim suspends the period on the conditions stated in Article 32(2) until written rejection and return of the documents attached to the claim.

Quality investigations can take weeks. Do not assume that internal batch review, insurer correspondence or settlement discussions preserve the CMR action period. Keep a separate deadline calculation from the first day.

9. Article 31 identifies the treaty forums for a Turkey–France CMR dispute

Article 31 permits proceedings, in addition to a Contracting-State forum validly designated by agreement, in the country where the defendant has the specified ordinary residence, principal place of business or contracting branch/agency, where the goods were taken over, or where the place designated for delivery is situated. Proceedings may not be brought elsewhere under Article 31(1).

For a France-to-Türkiye pharmaceutical shipment designated for delivery in Mersin, Türkiye can be a CMR forum through the delivery connection. For a Türkiye-to-France shipment taken over in Türkiye, the taking-over place can provide another Turkish connection. The exact defendant and carriage contract must still be identified.

Once Türkiye is available as a treaty forum, Turkish procedural law determines the competent Turkish court and any procedural prerequisite applicable to the specific dispute. Jurisdiction should be fixed before sending pleadings or allowing a limitation period to approach expiry.

Frequently asked questions

Official sources

UNIDROIT — CMR Convention, Articles 17, 18, 23–26, 29–32; United Nations Treaty Collection — 1978 Protocol to CMR. The treaty text, accepted carriage instructions and product-specific technical evidence determine the individual claim.